Proteinase-activated receptors (PARs) - Focus on receptor-receptor- interactions and their physiological and pathophysiological impact

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Gieseler, Frank ^a   Ungefroren, Hendrik ^a   Settmacher, Utz ^b   Hollenberg, Morley D ^c   Kaufmann, Roland ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ARRESTIN; CAPSAZEPINE; DELTIBANT; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 7 DEXTRO PHENYLALANINE]; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; ICATIBANT; ION CHANNEL; KETAMINE; LY 2109761; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 AGONIST; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR 4 ANTAGONIST; SX 007; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEIN SERINE THREONINE KINASE; RETINA S ANTIGEN;

AMINO TERMINAL SEQUENCE; ARTERY OCCLUSION; ARTHRITIS; BINDING SITE; CANCER GROWTH; CARDIOVASCULAR DISEASE; DIMERIZATION; DRUG TARGETING; EMBRYO DEVELOPMENT; HEMOSTASIS; HUMAN; INFECTION; INFLAMMATION; LUNG FIBROSIS; NEOPLASM; NERVE DEGENERATION; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; WOUND HEALING; ANIMAL; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; TRANSCRIPTION INITIATION;

ANIMALS; ARRESTINS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; PAIN; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR CROSS-TALK; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84887338267     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-86     Document Type: Review

References (257)

1. Guide to receptors and channels (GRAC), 3rd edition. Alexander SP, Mathie A, Peters JA, Br J Pharmacol 2008 153 Suppl 2 1 S209 18347570
2. International union of pharmacology. XXVIII. Proteinase-activated receptors. Hollenberg M, Compton S, Pharmacol Rev 2002 54 203 217 10.1124/pr.54.2.203 12037136 (Pubitemid 34575710)
3. Protease-activated receptors: contribution to physiology and disease. Ossovskaya V, Bunnett N, Physiol Rev 2004 84 579 621 10.1152/physrev.00028.2003 15044683 (Pubitemid 38365493)
4. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Ramachandran R, Hollenberg M, Br J Pharmacol 2008 153 Suppl 1 263 S282 18059329
5. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger T, Hollenberg M, Endocr Rev 2005 26 1 43 15689571 (Pubitemid 40209385)
6. Structure, function and pathophysiology of protease activated receptors. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD, Pharmacol Ther 2011 130 248 282 10.1016/j.pharmthera.2011.01.003 21277892
7. Targeting proteinase-activated receptors: therapeutic potential and challenges. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD, Nat Rev Drug Discov 2012 11 69 86 10.1038/nrd3615 22212680
8. Molecular tinkering of G protein-coupled receptors: an evolutionary success. Bockaert J, Pin JP, EMBO J 1999 18 1723 1729 10.1093/emboj/18.7.1723 10202136 (Pubitemid 29158516)
9. Mammalian G proteins and their cell type specific functions. Wettschureck N, Offermanns S, Physiol Rev 2005 85 1159 1204 10.1152/physrev.00003.2005 16183910 (Pubitemid 41362268)
10. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Vu T, Hung D, Wheaton V, Coughlin S, Cell 1991 64 1057 1068 10.1016/0092-8674(91)90261-V 1672265 (Pubitemid 121001193)
11. Neutrophil elastase and proteinase-3 trigger G-protein biased signaling through proteinase activated receptor-1 (PAR1). Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD, J Biol Chem 2013 Sep 19. [Epub ahead of print]
12. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A, Cell 2005 120 303 313 10.1016/j.cell.2004.12.018 15707890 (Pubitemid 40222426)
13. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A, Cell 2009 137 332 343 10.1016/j.cell.2009.02.018 19379698
14. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Muruve DA, DeFea KA, Bouvier M, Hollenberg MD, J Biol Chem 2011 286 24638 24648 10.1074/jbc.M110.201988 21576245
15. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M, J Thromb Haemost 2012 10 1675 1684 10.1111/j.1538-7836.2012.04825.x 22712885
16. PAR3 is a cofactor for PAR4 activation by thrombin. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR, Nature 2000 404 609 613 10.1038/35007085 10766244 (Pubitemid 30205059)
17. The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release. Ostrowska E, Reiser G, Cell Mol Life Sci 2008 65 970 981 10.1007/s00018-008-7555-y 18264801
18. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH, Blood 2012 120 5237 5246 10.1182/blood-2012-08-452169 23149848
19. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pagès G, Pavirani A, Lecocq JP, Pouysségur J, Van Obberghen-Schilling E, FEBS Lett 1991 288 123 128 10.1016/0014-5793(91)81017-3 1652467
20. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TK, Wheaton VI, Turck CW, Coughlin SR, J Biol Chem 1992 267 13146 13149 1320011
21. Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. Hansen KK, Saifeddine M, Hollenberg MD, Immunology 2004 112 183 190 10.1111/j.1365-2567.2004.01870.x 15147561 (Pubitemid 38703564)
22. Proteinase-activated receptors (PARs)-the PAR3 Neo-N-terminal peptide TFRGAP interacts with PAR1. Kaufmann R, Schulze B, Krause G, Mayr LM, Settmacher U, Henklein P, Regul Pept 2005 125 61 66 10.1016/j.regpep.2004.07.032 15582715 (Pubitemid 39593709)
23. Proteinase-activated receptors. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R, Pharmacol Rev 2001 53 245 282 11356985 (Pubitemid 32476117)
24. Proteases display biased agonism at protease-activated receptors: location matters! Russo A, Soh UJ, Trejo J, Mol Interv 2009 9 87 96 10.1124/mi.9.2.8 19401541
25. Protease-activated receptors in hemostasis, thrombosis and vascular biology. Coughlin SR, J Thromb Haemost 2005 3 1800 1814 10.1111/j.1538-7836. 2005.01377.x 16102047 (Pubitemid 41716567)
26. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. Hung DT, Wong YH, Vu TK, Coughlin SR, J Biol Chem 1992 267 20831 20834 1328213
27. Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. Rahman A, True AL, Anwar KN, Ye RD, Voyno-Yasenetskaya TA, Malik AB, Circ Res 2002 91 398 405 10.1161/01.RES.0000033520.95242.A2 12215488 (Pubitemid 35034207)
28. Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Ramachandran R, Mihara K, Mathur M, Rochdi MD, Bouvier M, Defea K, Hollenberg MD, Mol Pharmacol 2009 76 791 801 10.1124/mol.109.055509 19605524
29. Transduction of receptor signals by beta-arrestins. Lefkowitz RJ, Shenoy SK, Science 2005 308 512 517 10.1126/science.1109237 15845844 (Pubitemid 40570575)
30. Seven-transmembrane receptor signaling through beta-arrestin. Shenoy SK, Lefkowitz RJ, Sci STKE 2005 2005 m10 16267056
31. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Defea K, Br J Pharmacol 2008 153 Suppl 1 298 S309 18037927
32. Termination of protease-activated receptor-1 signaling by beta-arrestins is independent of receptor phosphorylation. Chen CH, Paing MM, Trejo J, J Biol Chem 2004 279 10020 10031 14699102 (Pubitemid 38372605)
33. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. Ge L, Shenoy SK, Lefkowitz RJ, DeFea K, J Biol Chem 2004 279 55419 55424 10.1074/jbc. M410312200 15489220 (Pubitemid 40066542)
34. Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2. Wang P, Jiang Y, Wang Y, Shyy JY, DeFea KA, BMC Biochem 2010 11 36 10.1186/1471-2091-11-36 20858278
35. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA, J Biol Chem 2007 282 20634 20646 10.1074/jbc.M701391200 17500066 (Pubitemid 47100047)
36. Structural insights into G-protein-coupled receptor activation. Weis WI, Kobilka BK, Curr Opin Struct Biol 2008 18 734 740 10.1016/j.sbi.2008.09.010 18957321
37. G protein-coupled receptors. II. Mechanism of agonist activation. Gether U, Kobilka BK, J Biol Chem 1998 273 17979 17982 10.1074/jbc.273.29.17979 9660746 (Pubitemid 28334705)
38. The non-stoichiometric floating receptor model for hormone sensitive adenylyl cyclase. de Haën C, J Theor Biol 1976 58 383 400 10.1016/S0022-5193(76)80126-9 181640
39. The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. Jacobs S, Cuatrecasas P, Biochim Biophys Acta 1976 433 482 495 10.1016/0005-2736(76)90275-3 179590
40. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Kenakin T, Miller LJ, Pharmacol Rev 2010 62 265 304 10.1124/pr.108.000992 20392808
41. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Kenakin TP, Br J Pharmacol 2012 165 1659 1669 10.1111/j.1476-5381.2011.01749.x 22023017
42. The paradigm of G protein receptor transactivation: a mechanistic definition and novel example. Little PJ, Burch ML, Al-aryahi S, Zheng W, ScientificWorld Journal 2011 11 709 714 21442148
43. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Feistritzer C, Riewald M, Blood 2005 105 3178 3184 10.1182/blood-2004-10-3985 15626732
44. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG, J Biol Chem 2005 280 17286 17293 10.1074/jbc.M412427200 15710622 (Pubitemid 41389197)
45. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. Guo H, Zhao Z, Yang Q, Wang M, Bell RD, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV, J Neurosci 2013 33 6181 6190 10.1523/JNEUROSCI.4491-12.2013 23554499
46. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Daub H, Weiss F, Wallasch C, Ullrich A, Nature 1996 379 557 560 10.1038/379557a0 8596637 (Pubitemid 26049585)
47. Signal characteristics of G protein-transactivated EGF receptor. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A, EMBO J 1997 16 7032 7044 10.1093/emboj/16.23.7032 9384582 (Pubitemid 27520803)
48. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Ferguson SS, Barak LS, Zhang J, Caron MG, Can J Physiol Pharmacol 1996 74 1095 1110 10.1139/y96-124 9022829 (Pubitemid 27047505)
49. Transactivation joins multiple tracks to the ERK/MAPK cascade. Wetzker R, Böhmer F, Nat Rev Mol Cell Biol 2003 4 651 657 10.1038/nrm1173 12923527 (Pubitemid 36934967)
50. G protein coupled receptor transactivation: extending the paradigm to include serine/threonine kinase receptors. Burch ML, Osman N, Getachew R, Al-Aryahi S, Poronnik P, Zheng W, Hill MA, Little PJ, Int J Biochem Cell Biol 2012 44 722 727 10.1016/j.biocel.2012.01.018 22326998
51. Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2. Chandrasekharan UM, Waitkus M, Kinney CM, Walters-Stewart A, DiCorleto PE, Arterioscler Thromb Vasc Biol 2010 30 1983 1989 10.1161/ATVBAHA.110.212399 20671228
52. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Siegbahn A, Johnell M, Nordin A, Aberg M, Velling T, Arterioscler Thromb Vasc Biol 2008 28 135 141 17991872
53. Mußbach F, Henklein P, Settmacher U, Böhmer F-D, Kaufmann R, RTKs, ROS and PTPs are involved in signal transduction of proteinase-activated receptors 1, 2 and 4 in HEP-3B hepatocellular carcinoma cells. 16th Joint Meeting of the Signal Transduction Society (STS) Weimar, Germany: Cell Communication & Signaling 2012 110
54. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Kaufmann R, Oettel C, Horn A, Halbhuber K, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer F, et al. Carcinogenesis 2009 30 1487 1496 10.1093/carcin/bgp153 19546160
55. Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level. Kaufmann R, Hascher A, Mußbach F, Henklein P, Katenkamp K, Westermann M, Settmacher U, Histochem Cell Biol 2012 138 913 924 10.1007/s00418-012-1006-4 22892662
56. G-protein and tyrosine kinase receptor cross-talk in rat aortic smooth muscle cells: thrombin- and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor 1 receptor. Du J, Sperling LS, Marrero MB, Phillips L, Delafontaine P, Biochem Biophys Res Commun 1996 218 934 939 10.1006/bbrc.1996.0165 8579617
57. Growth factors and vascular smooth muscle cell growth responses. Delafontaine P, Eur Heart J 1998 19 Suppl G 18 G22 9717051
58. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. Delafontaine P, Anwar A, Lou H, Ku L, J Clin Invest 1996 97 139 145 10.1172/JCI118381 8550825
59. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. Burch ML, Ballinger ML, Yang SN, Getachew R, Itman C, Loveland K, Osman N, Little PJ, J Biol Chem 2010 285 26798 26805 10.1074/jbc.M109.092767 20571025
60. TGF-beta signaling in tumor suppression and cancer progression. Derynck R, Akhurst RJ, Balmain A, Nat Genet 2001 29 117 129 10.1038/ng1001-117 11586292 (Pubitemid 32952643)
61. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ, Davis GE, Chambers RC, Matthay MA, Sheppard D, J Clin Invest 2006 116 1606 1614 10.1172/JCI27183 16710477
62. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Nguyen QD, De Wever O, Bruyneel E, Hendrix A, Xie WZ, Lombet A, Leibl M, Mareel M, Gieseler F, Bracke M, Gespach C, Oncogene 2005 24 8240 8251 10.1038/sj.onc. 1208990 16091733 (Pubitemid 43250916)
63. Activin signaling as an emerging target for therapeutic interventions. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K, Cell Commun Signal 2009 7 15 10.1186/1478-811X-7-15 19538713
64. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. Liu Y, Ren W, Warburton R, Toksoz D, Fanburg BL, FASEB J 2009 23 2299 2306 10.1096/fj.08-127910 19244313
65. Transforming growth factor-beta 1 regulates Kir2.3 inward rectifier K + channels via phospholipase C and protein kinase C-delta in reactive astrocytes from adult rat brain. Perillan PR, Chen M, Potts EA, Simard JM, J Biol Chem 2002 277 1974 1980 10.1074/jbc.M107984200 11713246 (Pubitemid 34968777)
66. Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice. Takizawa T, Tamiya M, Hara T, Matsumoto J, Saito N, Kanke T, Kawagoe J, Hattori Y, J Pharmacol Sci 2005 98 99 102 10.1254/jphs.SCZ050138 15879675 (Pubitemid 40806134)
67. A protective role for protease-activated receptors in the airways. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD, Nature 1999 398 156 160 10.1038/18223 10086357 (Pubitemid 29135454)
68. A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. Morello S, Vellecco V, Roviezzo F, Maffia P, Cuzzocrea S, Cirino G, Cicala C, Biochem Pharmacol 2005 71 223 230 10.1016/j.bcp.2005.10.016 16300746 (Pubitemid 41713544)
69. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. Kawao N, Nagataki M, Nagasawa K, Kubo S, Cushing K, Wada T, Sekiguchi F, Ichida S, Hollenberg MD, MacNaughton WK, et al. J Pharmacol Exp Ther 2005 315 576 589 10.1124/jpet.105.089490 16120814 (Pubitemid 41500722)
70. Role of PGE(2) in protease-activated receptor-1, -2 and -4 mediated relaxation in the mouse isolated trachea. Lan RS, Knight DA, Stewart GA, Henry PJ, Br J Pharmacol 2001 132 93 100 10.1038/sj.bjp.0703776 11156565 (Pubitemid 32128438)
71. Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea. Henry PJ, D'Aprile A, Self G, Hong T, Mann TS, J Pharmacol Exp Ther 2005 314 995 1001 10.1124/jpet.105. 086124 15937152 (Pubitemid 41205962)
72. Stimulation of protease-activated receptor-2 inhibits airway eosinophilia, hyperresponsiveness and bronchoconstriction in a murine model of allergic inflammation. De Campo BA, Henry PJ, Br J Pharmacol 2005 144 1100 1108 10.1038/sj.bjp.0706150 15700024 (Pubitemid 40593008)
73. The lung as a privileged site for the beneficial actions of PGE2. Vancheri C, Mastruzzo C, Sortino MA, Crimi N, Trends Immunol 2004 25 40 46 10.1016/j.it.2003.11.001 14698283 (Pubitemid 38032806)
74. Prostanoids and the cough reflex. Maher SA, Belvisi MG, Lung 2010 188 Suppl 1 9 S12 19830488
75. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Kay LJ, Yeo WW, Peachell PT, Br J Pharmacol 2006 147 707 713 10.1038/sj.bjp.0706664 16432506
76. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. Takayama K, García-Cardena G, Sukhova GK, Comander J, Gimbrone MA, Libby P, J Biol Chem 2002 277 44147 44154 10.1074/jbc.M204810200 12215436 (Pubitemid 36157844)
77. Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis. Sastre B, del Pozo V, Mediators Inflamm 2012 2012 645383 22529528
78. The protease-activated receptor2 (PAR2)-prostaglandin E2-prostanoid EP receptor axis: a potential bronchoprotective unit in the respiratory tract? Henry PJ, Eur J Pharmacol 2006 533 156 170 10.1016/j.ejphar.2005.12.051 16483565 (Pubitemid 43340012)
79. Evidence that PAR2-triggered prostaglandin E2 (PGE2) formation involves the ERK-cytosolic phospholipase A2-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. Nagataki M, Moriyuki K, Sekiguchi F, Kawabata A, Cell Biochem Funct 2008 26 279 282 10.1002/cbf.1434 17708577 (Pubitemid 351373978)
80. Proteinase-activated receptor-2-triggered prostaglandin E(2) release, but not cyclooxygenase-2 upregulation, requires activation of the phosphatidylinositol 3-kinase/Akt / nuclear factor-kappaB pathway in human alveolar epithelial cells. Moriyuki K, Sekiguchi F, Matsubara K, Nishikawa H, Kawabata A, J Pharmacol Sci 2009 111 269 275 10.1254/jphs.09155FP 19881225
81. Curcumin Inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κB in human lung epithelial cells. Moriyuki K, Sekiguchi F, Matsubara K, Nishikawa H, Kawabata A, J Pharmacol Sci 2010 114 225 229 10.1254/jphs.10126SC 20838026
82. Prostaglandin E(2) inhibits proteinase-activated receptor 2-signal transduction through regulation of receptor internalization. Komatsu H, Enjouji S, Ito A, Ohama T, Sato K, J Vet Med Sci 2013 75 255 261 10.1292/jvms.12-0365 23064451
83. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA, J Immunol 2002 168 3577 3585 11907122 (Pubitemid 34250428)
84. Thrombin induces cyclooxygenase-2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. Lo HM, Chen CL, Tsai YJ, Wu PH, Wu WB, J Cell Biochem 2009 108 1143 1152 10.1002/jcb.22341 19739103
85. Downregulation of protease-activated receptor-1 in human lung fibroblasts is specifically mediated by the prostaglandin E receptor EP2 through cAMP elevation and protein kinase A. Sokolova E, Hartig R, Reiser G, FEBS J 2008 275 3669 3679 10.1111/j.1742-4658.2008.06511.x 18537828
86. EGFR transactivation in the regulation of SMC function. Kalmes A, Daum G, Clowes AW, Ann N Y Acad Sci 2001 947 42 54 discussion 54-55 11795306
87. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A, Nature 1999 402 884 888 10622253
88. Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway. Wang Z, Wang M, Carr BI, J Cell Physiol 2008 216 551 557 10.1002/jcp.21429 18330891 (Pubitemid 351898484)
89. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Sabri A, Short J, Guo J, Steinberg SF, Circ Res 2002 91 532 539 10.1161/01.RES. 0000035242.96310.45 12242272
90. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF, J Biol Chem 2003 278 11714 11720 10.1074/jbc.M213091200 12522105 (Pubitemid 36792735)
91. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. Abdallah RT, Keum JS, El-Shewy HM, Lee MH, Wang B, Gooz M, Luttrell DK, Luttrell LM, Jaffa AA, J Biol Chem 2010 285 35206 35215 10.1074/jbc.M110.171769 20826789
92. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Al-Ani B, Hewett P, Cudmore M, Fujisawa T, Saifeddine M, Williams H, Ramma W, Sissaoui S, Jayaraman P, Ohba M, et al. Hypertension 2010 55 689-U641
93. Proteinase-activated receptors, targets for kallikrein signaling. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, et al. J Biol Chem 2006 281 32095 32112 10.1074/jbc.M513138200 16885167 (Pubitemid 46036764)
94. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Oikonomopoulou K, Hansen K, Saifeddine M, Vergnolle N, Tea I, Diamandis E, Hollenberg M, Biol Chem 2006 387 677 685 16800728 (Pubitemid 43964789)
95. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, Hanakawa Y, Ohmoto H, Yoshino K, Shirakata Y, et al. J Cell Biol 2000 151 209 220 10.1083/jcb.151.2.209 11038170
96. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Gao L, Chao L, Chao J, Exp Cell Res 2010 316 376 389 10.1016/j.yexcr.2009.10.022 19879874
97. Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. Huang CY, Chen SY, Tsai HC, Hsu HC, Tang CH, Arthritis Rheum 2012 64 3344 3354 10.1002/art.34557 22674286
98. Recent developments in CCR2 antagonists. Xia M, Sui Z, Expert Opin Ther Pat 2009 19 295 303 10.1517/13543770902755129 19441905
99. The pronociceptive effect of proteinase-activated receptor-4 stimulation in rat knee joints is dependent on mast cell activation. Russell FA, Zhan S, Dumas A, Lagarde S, Pouliot M, McDougall JJ, Pain 2011 152 354 360 10.1016/j.pain.2010.10.038 21238854
100. Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation. Russell FA, McDougall JJ, Inflamm Res 2009 58 119 126 10.1007/s00011-009-8087-0 19184346
101. Proteinase-activated receptor-2 (PAR(2)) activation sensitises primary afferents and causes leukocyte rolling and adherence in the rat knee joint. Russell FA, Schuelert N, Veldhoen VE, Hollenberg MD, McDougall JJ, Br J Pharmacol 2012 167 1665 1678 10.1111/j.1476-5381.2012.02120.x 22849826
102. Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism. Russell FA, Veldhoen VE, Tchitchkan D, McDougall JJ, J Neurophysiol 2010 103 155 163 10.1152/jn.00486.2009 19889854
103. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, Sommerhoff CP, McLean JS, Ferrell WR, J Pharmacol Exp Ther 2006 316 1017 1024 16260582 (Pubitemid 43345273)
104. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, Chambers RC, Am J Pathol 2005 166 1353 1365 10.1016/S0002-9440(10)62354-1 15855637 (Pubitemid 40586507)
105. Involvement of Rho signaling in PAR2-mediated regulation of neutrophil adhesion to lung epithelial cells. Yagi Y, Otani H, Ando S, Oshiro A, Kawai K, Nishikawa H, Araki H, Fukuhara S, Inagaki C, Eur J Pharmacol 2006 536 19 27 10.1016/j.ejphar.2006.02.024 16564523
106. Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. Arizmendi NG, Abel M, Mihara K, Davidson C, Polley D, Nadeem A, El Mays T, Gilmore BF, Walker B, Gordon JR, et al. J Immunol 2011 186 3164 3172 10.4049/jimmunol. 0903812 21270400
107. β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Nichols HL, Saffeddine M, Theriot BS, Hegde A, Polley D, El-Mays T, Vliagoftis H, Hollenberg MD, Wilson EH, Walker JK, Defea KA, Proc Natl Acad Sci U S A 2012 109 16660 16665 10.1073/pnas.1208881109 23012429
108. Proteinase-activated receptor 4 stimulation-induced epithelial- mesenchymal transition in alveolar epithelial cells. Ando S, Otani H, Yagi Y, Kawai K, Araki H, Fukuhara S, Inagaki C, Respir Res 2007 8 31 10.1186/1465-9921-8-31 17433115
109. Signal transduction for formation/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells. Moriyuki K, Nagataki M, Sekiguchi F, Nishikawa H, Kawabata A, Regul Pept 2008 145 42 48 10.1016/j.regpep.2007.08.002 17854923 (Pubitemid 350296353)
110. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Bhola NE, Grandis JR, Front Biosci 2008 13 1857 1865 10.2741/2805 17981673 (Pubitemid 351599738)
111. PAR-type thrombin receptors in renal carcinoma cells: PAR(1)-mediated EGFR activation promotes cell migration. Bergmann S, Junker K, Henklein P, Hollenberg MD, Settmacher U, Kaufmann R, Oncol Rep 2006 15 889 893 16525676
112. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M, Mol Cancer Res 2004 2 514 522 15383630 (Pubitemid 39281733)
113. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. Darmoul D, Gratio V, Devaud H, Laburthe M, J Biol Chem 2004 279 20927 20934 10.1074/jbc.M401430200 15010475 (Pubitemid 38656491)
114. PAR-2 activation increases human intestinal mucin secretion through EGFR transactivation. Jarry A, Dorso L, Gratio V, Forgue-Lafitte M, Laburthe M, Laboisse C, Darmoul D, Biochem Biophys Res Commun 2007 364 689 694 10.1016/j.bbrc.2007.10.073 18028876 (Pubitemid 350030925)
115. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. van der Merwe JQ, Hollenberg MD, MacNaughton WK, Am J Physiol Gastrointest Liver Physiol 2008 294 441 G451 18032480
116. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli L, Palmieri G, et al. Am J Pathol 2006 169 268 278 10.2353/ajpath.2006.050841 16816379
117. The activation of proteinase-activated receptor-1 (PAR1) mediates gastric cancer cell proliferation and invasion. Fujimoto D, Hirono Y, Goi T, Katayama K, Matsukawa S, Yamaguchi A, BMC Cancer 2010 10 443 10.1186/1471-2407-10-443 20723226
118. Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D, Int J Cancer 2009 124 1517 1525 10.1002/ijc.24070 19058300
119. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Gratio V, Loriot C, Virca GD, Oikonomopoulou K, Walker F, Diamandis EP, Hollenberg MD, Darmoul D, Am J Pathol 2011 179 2625 2636 10.1016/j.ajpath.2011.07.016 21907696
120. Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors. Chung H, Hamza M, Oikonomopoulou K, Gratio V, Saifeddine M, Virca GD, Diamandis EP, Hollenberg MD, Darmoul D, Biol Chem 2012 393 413 420 22505523
121. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M, Am J Pathol 2003 162 1503 1513 10.1016/S0002-9440(10)64283-6 12707033 (Pubitemid 36512832)
122. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J, Oncogene 2008 27 4434 4445 10.1038/onc.2008.84 18372913
123. Inflammation and cancer: how hot is the link? Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G, Biochem Pharmacol 2006 72 1605 1621 10.1016/j.bcp.2006.06.029 16889756 (Pubitemid 44666739)
124. Multifaceted link between cancer and inflammation. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V, Biosci Rep 2012 32 1 15 10.1042/BSR20100136 21981137
125. Protease-activated receptor 2 signaling in inflammation. Rothmeier AS, Ruf W, Semin Immunopathol 2012 34 133 149 10.1007/s00281-011-0289-1 21971685
126. Gastrointestinal roles for proteinase-activated receptors in health and disease. Kawabata A, Matsunami M, Sekiguchi F, Br J Pharmacol 2008 153 Suppl 1 230 S240 17994114
127. Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Hirota CL, Moreau F, Iablokov V, Dicay M, Renaux B, Hollenberg MD, MacNaughton WK, Am J Physiol Gastrointest Liver Physiol 2012 303 111 G119 10.1152/ajpgi.00358.2011 22517768
128. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Milligan G, Br J Pharmacol 2009 158 5 14 10.1111/j.1476-5381.2009.00169.x 19309353
129. Oligomerization of G-protein-coupled transmitter receptors. Bouvier M, Nat Rev Neurosci 2001 2 274 286 10.1038/35067575 11283750 (Pubitemid 33673068)
130. G-protein-coupled receptor oligomerization and its potential for drug discovery. George SR, O'Dowd BF, Lee SP, Nat Rev Drug Discov 2002 1 808 820 10.1038/nrd913 12360258 (Pubitemid 37361564)
131. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Breitwieser GE, Circ Res 2004 94 17 27 10.1161/01.RES.0000110420.68526.19 14715532 (Pubitemid 38064094)
132. G-protein-coupled receptor heterodimerization modulates receptor function. Jordan BA, Devi LA, Nature 1999 399 697 700 10.1038/21441 10385123 (Pubitemid 29289066)
133. Building a new conceptual framework for receptor heteromers. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, et al. Nat Chem Biol 2009 5 131 134 10.1038/nchembio0309-131 19219011
134. Fine-tuning of GPCR activity by receptor-interacting proteins. Ritter SL, Hall RA, Nat Rev Mol Cell Biol 2009 10 819 830 19935667
135. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF, J Biol Chem 2000 275 13502 13509 10.1074/jbc.275.18. 13502 10788464 (Pubitemid 30257415)
136. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. Chen J, Ishii M, Wang L, Ishii K, Coughlin SR, J Biol Chem 1994 269 16041 16045 8206902
137. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Shi X, Gangadharan B, Brass L, Ruf W, Mueller B, Mol Cancer Res 2004 2 395 402 15280447 (Pubitemid 39031073)
138. The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells. Kaufmann R, Patt S, Zieger M, Kraft R, Tausch S, Henklein P, Nowak G, J Cancer Res Clin Oncol 2000 126 91 94 10.1007/PL00008481 10664248 (Pubitemid 30062966)
139. Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. Vesey DA, Cheung CW, Kruger WA, Poronnik P, Gobe G, Johnson DW, Kidney Int 2005 67 1315 1329 10.1111/j.1523-1755.2005.00209.x 15780084 (Pubitemid 40463108)
140. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P, J Pharmacol Exp Ther 1999 288 671 678 9918574 (Pubitemid 29119680)
141. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N, Blood 2010 116 5037 5044 10.1182/blood-2010-06-293126 20736455
142. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. Cottrell GS, Amadesi S, Grady EF, Bunnett NW, J Biol Chem 2004 279 13532 13539 10.1074/jbc.M312090200 14726524 (Pubitemid 38468878)
143. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A, Circulation 2006 113 1244 1254 10.1161/CIRCULATIONAHA.105.587758 16505172
144. G protein-coupled receptor dimerization: function and ligand pharmacology. Milligan G, Mol Pharmacol 2004 66 1 7 10.1124/mol.104.000497. 15213289 (Pubitemid 38822080)
145. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ, Nat Methods 2006 3 1001 1006 10.1038/nmeth978 17086179 (Pubitemid 44782699)
146. Use of fluorescence resonance energy transfer to analyze oligomerization of G-protein-coupled receptors expressed in yeast. Overton MC, Blumer KJ, Methods 2002 27 324 332 10.1016/S1046-2023(02)00090-7 12217648
147. Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization. Cottet M, Albizu L, Comps-Agrar L, Trinquet E, Pin JP, Mouillac B, Durroux T, Methods Mol Biol 2011 746 373 387 10.1007/978-1-61779-126-0-21 21607869
148. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to G protein-coupled receptor oligomerization. Comps-Agrar L, Maurel D, Rondard P, Pin JP, Trinquet E, Prézeau L, Methods Mol Biol 2011 756 201 214 10.1007/978-1-61779-160-4-10 21870227
149. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A, Nat Immunol 2007 8 1303 1312 10.1038/ni1525 17965715 (Pubitemid 350131169)
150. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Sevigny LM, Austin KM, Zhang P, Kasuda S, Koukos G, Sharifi S, Covic L, Kuliopulos A, Arterioscler Thromb Vasc Biol 2011 31 100 e106 10.1161/ATVBAHA.111.238261 21940952
151. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds. Soh UJ, Trejo J, Proc Natl Acad Sci U S A 2011 108 1372 E1380 10.1073/pnas.1112482108 22106258
152. Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. Lin H, Trejo J, J Biol Chem 2013 288 11203 11215 10.1074/jbc.M112.439950 23476015
153. A dual thrombin receptor system for platelet activation. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR, Nature 1998 394 690 694 10.1038/29325 9716134 (Pubitemid 28389797)
154. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR, J Clin Invest 1999 103 879 887 10.1172/JCI6042 10079109 (Pubitemid 29152634)
155. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1. Nieman MT, Biochemistry 2008 47 13279 13286 10.1021/bi801334s 19053259
156. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Covic L, Gresser AL, Kuliopulos A, Biochemistry 2000 39 5458 5467 10.1021/bi9927078 10820018 (Pubitemid 30257087)
157. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR, J Biol Chem 2000 275 25216 25221 10.1074/jbc.M004589200 10837487
158. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M, Hollenberg M, Settmacher U, J Cell Physiol 2007 211 699 707 10.1002/jcp.21027 17323377 (Pubitemid 46683038)
159. Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E, Proc Natl Acad Sci USA 2007 104 11603 11608 10.1073/pnas.0704409104 17606903 (Pubitemid 47175059)
160. Thrombin receptor expression in normal and atherosclerotic human arteries. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR, J Clin Invest 1992 90 1614 1621 10.1172/JCI116031 1328304
161. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. Mirza H, Yatsula V, Bahou WF, J Clin Invest 1996 97 1705 1714 10.1172/JCI118597 8601636
162. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF, J Biol Chem 1998 273 15061 15068 10.1074/jbc.273.24.15061 9614115 (Pubitemid 28272801)
163. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR, Blood 2003 102 3224 3231 10.1182/blood-2003-04-1130 12869501 (Pubitemid 37314759)
164. Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. Fujiwara M, Jin E, Ghazizadeh M, Kawanami O, J Histochem Cytochem 2005 53 1121 1129 10.1369/jhc.4A6592.2005 15923365 (Pubitemid 41262980)
165. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. McLaughlin JN, Patterson MM, Malik AB, Proc Natl Acad Sci USA 2007 104 5662 5667 10.1073/pnas.0700763104 17376866 (Pubitemid 47175737)
166. Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4). Cunningham MR, McIntosh KA, Pediani JD, Robben J, Cooke AE, Nilsson M, Gould GW, Mundell S, Milligan G, Plevin R, J Biol Chem 2012 287 16656 16669 10.1074/jbc.M111.315911 22411985
167. Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. de la Fuente M, Noble DN, Verma S, Nieman MT, J Biol Chem 2012 287 10414 10423 10.1074/jbc.M112.341438 22318735
168. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. Dorsam RT, Tuluc M, Kunapuli SP, J Thromb Haemost 2004 2 804 812 10.1111/j.1538-7836.2004.00692.x 15099288 (Pubitemid 40185718)
169. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP, J Thromb Haemost 2006 4 638 647 10.1111/j.1538-7836.2006.01789.x 16460446
170. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Henriksen RA, Hanks VK, Arterioscler Thromb Vasc Biol 2002 22 861 866 10.1161/01.ATV.0000014742.56572.25 12006403 (Pubitemid 34517802)
171. Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. Henriksen RA, Samokhin GP, Tracy PB, Arterioscler Thromb Vasc Biol 1997 17 3519 3526 10.1161/01.ATV.17.12.3519 9437201 (Pubitemid 28028564)
172. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Teng CM, Thromb Haemost 2003 90 299 308 12888878
173. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. Li D, D'Angelo L, Chavez M, Woulfe DS, J Biol Chem 2011 286 3805 3814 10.1074/jbc.M110.118018 21106537
174. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Hollenberg MD, Saifeddine M, Sandhu S, Houle S, Vergnolle N, Br J Pharmacol 2004 143 443 454 10.1038/sj.bjp.0705946 15451771 (Pubitemid 39452212)
175. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. Vergnolle N, Derian CK, D'Andrea MR, Steinhoff M, Andrade-Gordon P, J Immunol 2002 169 1467 1473 12133973 (Pubitemid 34809192)
176. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N, Br J Pharmacol 2005 146 670 678 10.1038/sj.bjp. 0706371 16100525 (Pubitemid 41573618)
177. Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice. McDougall JJ, Zhang C, Cellars L, Joubert E, Dixon CM, Vergnolle N, Arthritis Rheum 2009 60 728 737 10.1002/art.24300 19248120
178. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Hatton MW, Moar SL, Richardson M, Am J Pathol 1989 135 499 508 2782381 (Pubitemid 19246208)
179. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. Effect of heparin. Herbert JM, Lamarche I, Dol F, FEBS Lett 1992 301 155 158 10.1016/0014-5793(92)81237-G 1314739
180. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK, J Clin Invest 1993 91 94 98 10.1172/JCI116206 8380817 (Pubitemid 23037258)
181. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Hirano K, Arterioscler Thromb Vasc Biol 2007 27 27 36 10.1161/01.ATV.0000251995.73307.2d 17095716 (Pubitemid 46370476)
182. Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. Fukunaga R, Hirano K, Hirano M, Niiro N, Nishimura J, Maehara Y, Kanaide H, Am J Physiol Heart Circ Physiol 2006 291 2388 H2395 10.1152/ajpheart.01313.2005 16844909
183. Characterization of thrombin receptor expression during vascular lesion formation. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Circ Res 1994 75 1029 1038 10.1161/01.RES.75.6.1029 7955141 (Pubitemid 24351448)
184. Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases. Schini-Kerth VB, Fisslthaler B, Van Obberghen-Schilling E, Busse R, Circulation 1996 93 2170 2177 10.1161/01.CIR.93.12.2170 8925586
185. Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells. Fisslthaler B, Schini-Kerth VB, Fleming I, Busse R, Cardiovasc Res 1998 38 263 271 10.1016/S0008-6363(97)00296-4 9683930 (Pubitemid 28275638)
186. Vascular thrombin receptor regulation in hypertensive rats. Capers Q, Laursen JB, Fukui T, Rajagopalan S, Mori I, Lou P, Freeman BA, Berrington WR, Griendling KK, Harrison DG, et al. Circ Res 1997 80 838 844 10.1161/01.RES.80.6. 838 9168786 (Pubitemid 27230058)
187. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. Rallabhandi P, Nhu QM, Toshchakov VY, Piao W, Medvedev AE, Hollenberg MD, Fasano A, Vogel SN, J Biol Chem 2008 283 24314 24325 10.1074/jbc.M804800200 18622013
188. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, Vogel SN, Mucosal Immunol 2010 3 29 39 10.1038/mi.2009.120 19865078
189. Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages. Nhu QM, Shirey KA, Pennini ME, Stiltz J, Vogel SN, Innate Immun 2012 18 193 203 10.1177/1753425910395044 21239455
190. Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2. Zhou B, Zhou H, Ling S, Guo D, Yan Y, Zhou F, Wu Y, Oncol Rep 2011 25 503 511 21152870
191. Role of PAR2 in murine pulmonary pseudomonal infection. Moraes TJ, Martin R, Plumb JD, Vachon E, Cameron CM, Danesh A, Kelvin DJ, Ruf W, Downey GP, Am J Physiol Lung Cell Mol Physiol 2008 294 368 L377 18083764
192. The contribution of PARs to inflammation and immunity to fungi. Moretti S, Bellocchio S, Bonifazi P, Bozza S, Zelante T, Bistoni F, Romani L, Mucosal Immunol 2008 1 156 168 10.1038/mi.2007.13 19079173
193. Cross-talk between toll-like receptor 4 (TLR4) and proteinase-activated receptor 2 (PAR(2)) is involved in vascular function. Bucci M, Vellecco V, Harrington L, Brancaleone V, Roviezzo F, Mattace Raso G, Ianaro A, Lungarella G, De Palma R, Meli R, Cirino G, Br J Pharmacol 2013 168 411 420 10.1111/j.1476-5381.2012.02205.x 22957757
194. NOD-like receptors and the innate immune system: coping with danger, damage and death. Kersse K, Bertrand MJ, Lamkanfi M, Vandenabeele P, Cytokine Growth Factor Rev 2011 22 257 276 10.1016/j.cytogfr.2011.09.003 21996492
195. Gingipains from Porphyromonas gingivalis synergistically induce the production of proinflammatory cytokines through protease-activated receptors with Toll-like receptor and NOD1/2 ligands in human monocytic cells. Uehara A, Imamura T, Potempa J, Travis J, Takada H, Cell Microbiol 2008 10 1181 1189 10.1111/j.1462-5822.2008.01119.x 18182086 (Pubitemid 351524281)
196. Potentiation of NMDA receptor function by the serine protease thrombin. Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF, J Neurosci 2000 20 4582 4595 10844028 (Pubitemid 30396624)
197. Serine protease inhibitors: novel therapeutic targets for stroke? Vivien D, Buisson A, J Cereb Blood Flow Metab 2000 20 755 764 10826525 (Pubitemid 30317049)
198. Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? Matsuoka H, Hamada R, CNS Drugs 2002 16 509 516 10.2165/00023210-200216080-00001 12096932 (Pubitemid 34827908)
199. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? Xi G, Reiser G, Keep RF, J Neurochem 2003 84 3 9 12485396 (Pubitemid 36182060)
200. PAR1 signaling: more good than harm? Ruf W, Nat Med 2003 9 258 260 10.1038/nm0303-258 12612568 (Pubitemid 36362775)
201. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Sheehan JJ, Tsirka SE, Glia 2005 50 340 350 10.1002/glia.20150 15846799 (Pubitemid 40780840)
202. Astrocytic control of synaptic NMDA receptors. Lee CJ, Mannaioni G, Yuan H, Woo DH, Gingrich MB, Traynelis SF, J Physiol 2007 581 1057 1081 10.1113/jphysiol.2007.130377 17412766 (Pubitemid 46887980)
203. Cloning by functional expression of a member of the glutamate receptor family. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S, Nature 1989 342 643 648 10.1038/342643a0 2480522 (Pubitemid 20001579)
204. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. Mannaioni G, Orr AG, Hamill CE, Yuan H, Pedone KH, McCoy KL, Berlinguer Palmini R, Junge CE, Lee CJ, Yepes M, et al. J Biol Chem 2008 283 20600 20611 10.1074/jbc.M803015200 18474593
205. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. Nagai T, Ito M, Nakamichi N, Mizoguchi H, Kamei H, Fukakusa A, Nabeshima T, Takuma K, Yamada K, J Neurosci 2006 26 12374 12383 10.1523/JNEUROSCI.3139-06.2006 17122062 (Pubitemid 44808404)
206. Special lecture: glial reactivity after damage: implications for scar formation and neuronal recovery. Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ, Traynelis SF, Clin Neurosurg 2005 52 29 44 16626052
207. Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Hamill CE, Mannaioni G, Lyuboslavsky P, Sastre AA, Traynelis SF, Exp Neurol 2009 217 136 146 10.1016/j.expneurol.2009.01.023 19416668
208. Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus. Han KS, Mannaioni G, Hamill CE, Lee J, Junge CE, Lee CJ, Traynelis SF, Mol Brain 2011 4 32 10.1186/1756-6606-4-32 21827709
209. Purinergic signalling in neuron-glia interactions. Fields RD, Burnstock G, Nat Rev Neurosci 2006 7 423 436 10.1038/nrn1928 16715052 (Pubitemid 44012283)
210. Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. Shigetomi E, Bowser DN, Sofroniew MV, Khakh BS, J Neurosci 2008 28 6659 6663 10.1523/JNEUROSCI.1717-08.2008 18579739
211. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C, J Immunol 2003 170 2638 2646 12594292 (Pubitemid 36245656)
212. Indirect modulation of neuronal excitability and synaptic transmission in the hippocampus by activation of proteinase-activated receptor-2. Gan J, Greenwood SM, Cobb SR, Bushell TJ, Br J Pharmacol 2011 163 984 994 10.1111/j.1476-5381.2011.01293.x 21366553
213. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. Grenegård M, Vretenbrant-Oberg K, Nylander M, Désilets S, Lindström EG, Larsson A, Ramström I, Ramström S, Lindahl TL, J Biol Chem 2008 283 18493 18504 10.1074/jbc.M800358200 18480058
214. An introduction to TRP channels. Ramsey IS, Delling M, Clapham DE, Annu Rev Physiol 2006 68 619 647 10.1146/annurev.physiol.68.040204.100431 16460286
215. International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Wu LJ, Sweet TB, Clapham DE, Pharmacol Rev 2010 62 381 404 10.1124/pr.110.002725 20716668
216. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, et al. Nat Med 2000 6 151 158 10.1038/72247 10655102 (Pubitemid 30082358)
217. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, et al. Br J Pharmacol 2001 133 975 987 10.1038/sj.bjp.0704152 11487506 (Pubitemid 32762406)
218. The proteinase-activated receptor 2 is involved in nociception. Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee-Hellmich H, Xiao SY, Winston JH, Pasricha PJ, J Neurosci 2001 21 9036 9042 11698614 (Pubitemid 33054865)
219. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. Dai Y, Moriyama T, Higashi T, Togashi K, Kobayashi K, Yamanaka H, Tominaga M, Noguchi K, J Neurosci 2004 24 4293 4299 10.1523/JNEUROSCI.0454-04.2004 15128843 (Pubitemid 38612819)
220. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, et al. J Neurosci 2004 24 4300 4312 10.1523/JNEUROSCI. 5679-03.2004 15128844 (Pubitemid 38608141)
221. Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. Kawabata A, Kawao N, Kuroda R, Tanaka A, Itoh H, Nishikawa H, Neuroreport 2001 12 715 719 10.1097/00001756-200103260-00020 11277570 (Pubitemid 32222704)
222. Protease-activated receptors: Mechanism by which proteases sensitize TRPV channels to induce neurogenic inflammation and pain. Grant A, Amadesi S, Bunnett NW, TRP ion channel function in sensory transduction and cellular signaling cascades Boca Raton (FL): CRC Press, WB L, Heller S, 2007
223. Understanding the signaling and transmission of visceral nociceptive events. Cervero F, Laird JM, J Neurobiol 2004 61 45 54 10.1002/neu.20084 15362152 (Pubitemid 39287769)
224. Roles of transient receptor potential channels in pain. Stucky CL, Dubin AE, Jeske NA, Malin SA, McKemy DD, Story GM, Brain Res Rev 2009 60 2 23 10.1016/j.brainresrev.2008.12.018 19203589
225. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanjia R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnett NW, J Physiol 2006 575 555 571 10.1113/jphysiol.2006. 111534 16793902 (Pubitemid 44270181)
226. The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. Nishimura S, Ishikura H, Matsunami M, Shinozaki Y, Sekiguchi F, Naruse M, Kitamura T, Akashi R, Matsumura K, Kawabata A, Life Sci 2010 87 643 650 10.1016/j.lfs.2010.09.030 20932849
227. Proteinase-activated receptor 2 mediates thermal hyperalgesia and is upregulated in a rat model of chronic pancreatitis. Zhang W, Gao J, Zhao T, Wei L, Wu W, Bai Y, Zou D, Li Z, Pancreas 2011 40 300 307 10.1097/MPA. 0b013e318201cbc1 21311307
228. Lesioning of TRPV1 expressing primary afferent neurons prevents PAR-2 induced motility, but not mechanical hypersensitivity in the rat colon. Suckow SK, Anderson EM, Caudle RM, Neurogastroenterol Motil 2012 24 125 e135 10.1111/j.1365-2982.2011.01848.x 22168801
229. PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts. Jiang R, Zatta A, Kin H, Wang N, Reeves JG, Mykytenko J, Deneve J, Zhao ZQ, Guyton RA, Vinten-Johansen J, Am J Physiol Heart Circ Physiol 2007 293 2845 H2852 10.1152/ajpheart.00209.2007 17720772 (Pubitemid 350106507)
230. Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G, Proc Natl Acad Sci USA 2000 97 3678 3683 10.1073/pnas.97.7.3678 10737808 (Pubitemid 30183362)
231. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Napoli C, De Nigris F, Cicala C, Wallace JL, Caliendo G, Condorelli M, Santagada V, Cirino G, Am J Physiol Heart Circ Physiol 2002 282 2004 H2010 12003804
232. Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. McLean PG, Aston D, Sarkar D, Ahluwalia A, Circ Res 2002 90 465 472 10.1161/hh0402.105372 11884377 (Pubitemid 34633917)
233. Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors. Zhong B, Wang DH, Am J Physiol Regul Integr Comp Physiol 2009 297 1681 R1690 10.1152/ajpregu.90746.2008 19812353
234. Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurones. Vellani V, Kinsey AM, Prandini M, Hechtfischer SC, Reeh P, Magherini PC, Giacomoni C, McNaughton PA, Mol Pain 2010 6 61 10.1186/1744-8069-6-61 20875131
235. Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling. Poole DP, Amadesi S, Veldhuis NA, Abogadie FC, Lieu T, Darby W, Liedtke W, Lew MJ, McIntyre P, Bunnett NW, J Biol Chem 2013 288 5790 5802 10.1074/jbc.M112.438184 23288842
236. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Chen Y, Yang C, Wang ZJ, Neuroscience 2011 193 440 451 21763756
237. Signal transduction by protease-activated receptors. Soh UJ, Dores MR, Chen B, Trejo J, Br J Pharmacol 2010 160 191 203 10.1111/j.1476-5381.2010.00705. x 20423334
238. gp25L/emp24/p24 protein family members of the cis-Golgi network bind both COP I and II coatomer. Dominguez M, Dejgaard K, Füllekrug J, Dahan S, Fazel A, Paccaud JP, Thomas DY, Bergeron JJ, Nilsson T, J Cell Biol 1998 140 751 765 10.1083/jcb.140.4.751 9472029 (Pubitemid 28141215)
239. p24 Proteins, intracellular trafficking, and behavior: drosophila melanogaster provides insights and opportunities. Carney GE, Bowen NJ, Biol Cell 2004 96 271 278 15145531 (Pubitemid 38618755)
240. p24A, a type I transmembrane protein, controls ARF1-dependent resensitization of protease-activated receptor-2 by influence on receptor trafficking. Luo W, Wang Y, Reiser G, J Biol Chem 2007 282 30246 30255 10.1074/jbc.M703205200 17693410 (Pubitemid 350035298)
241. Proteinase-activated receptors, nucleotide P2Y receptors, and μ-opioid receptor-1B are under the control of the type I transmembrane proteins p23 and p24A in post-Golgi trafficking. Luo W, Wang Y, Reiser G, J Neurochem 2011 117 71 81 10.1111/j.1471-4159.2011.07173.x 21219331
242. International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, Spedding M, Pharmacol Rev 2007 59 5 13 10.1124/pr.59.1.5 17329545 (Pubitemid 46335687)
243. Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Ayoub MA, Pfleger KD, Curr Opin Pharmacol 2010 10 44 52 10.1016/j.coph.2009.09.012 19897419
244. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Milligan G, Curr Opin Pharmacol 2010 10 23 29 10.1016/j.coph.2009. 09.010 19850521
245. Dimerization in GPCR mobility and signaling. Lohse MJ, Curr Opin Pharmacol 2010 10 53 58 10.1016/j.coph.2009.10.007 19910252
246. Receptor heteromerization and drug discovery. Rozenfeld R, Devi LA, Trends Pharmacol Sci 2010 31 124 130 10.1016/j.tips.2009.11.008 20060175
247. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Kenakin T, Br J Pharmacol 2013 168 554 575 10.1111/j.1476-5381.2012.02223.x 22994528
248. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Barki-Harrington L, Luttrell LM, Rockman HA, Circulation 2003 108 1611 1618 10.1161/01.CIR.0000092166.30360.78 12963634 (Pubitemid 37187789)
249. High-resolution crystal structure of human protease-activated receptor 1. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, et al. Nature 2012 492 387 392 10.1038/nature11701 23222541
250. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A, Proc Natl Acad Sci USA 2011 108 8491 8496 10.1073/pnas.1017091108 21536878
251. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP, Br J Pharmacol 2012 165 1413 1423 10.1111/j.1476-5381. 2011.01610.x 21806599
252. Antagonism of protease-activated receptor 2 protects against experimental colitis. Lohman RJ, Cotterell AJ, Suen J, Liu L, Do AT, Vesey DA, Fairlie DP, J Pharmacol Exp Ther 2012 340 256 265 10.1124/jpet.111.187062 22028393
253. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, Fairlie DP, FASEB J 2012 26 2877 2887 10.1096/fj.11-201004 22467762
254. Biased signalling and proteinase-activated receptors (pars): targeting inflammatory disease. Hollenberg M, Mihara K, Polley D, Fairlie D, Ramachandran R, Brit J Pharmacol 2013 in press
255. Han A, Honours Dissertation Queensland: University of Queensland 2008
256. Targeting the transforming growth factor-beta signaling pathway in human cancer. Nagaraj NS, Datta PK, Expert Opin Investig Drugs 2010 19 77 91 10.1517/13543780903382609 20001556
257. Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. Kamato D, Burch ML, Osman N, Zheng W, Little PJ, J Pharm Pharmacol 2013 65 465 473 10.1111/j.2042-7158.2012.01577.x 23488775